Chemomab Therapeutics (CMMB) to Announce Quarterly Earnings on Thursday

Chemomab Therapeutics (NASDAQ:CMMB) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Chemomab Therapeutics to post earnings of ($0.04) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 20, 2026 at 12:30 PM ET.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.18). On average, analysts expect Chemomab Therapeutics to post $-0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chemomab Therapeutics Trading Down 2.1%

Chemomab Therapeutics stock opened at $1.89 on Tuesday. Chemomab Therapeutics has a 12-month low of $1.35 and a 12-month high of $4.12. The firm has a market capitalization of $13.61 million, a price-to-earnings ratio of -0.85 and a beta of 0.65. The firm has a 50 day moving average of $1.69 and a 200 day moving average of $1.70.

Institutional Trading of Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. XTX Topco Ltd acquired a new stake in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 19,013 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned approximately 0.31% of Chemomab Therapeutics as of its most recent SEC filing. Institutional investors own 46.05% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Chemomab Therapeutics in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $25.00.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.